Evidence map›Paper›PMID 35804998›Full record

ArticleCancers2022

Body Mass Index Is Inversely Associated with Risk of Postmenopausal Interval Breast Cancer: Results from the Women's Health Initiative.

Zhenzhen Zhang, Grace Curran, Jackilen Shannon, Ellen M Velie, Veronica L Irvin, JoAnn E Manson, Michael S Simon, Duygu Altinok Dindar, Chelsea Pyle, Pepper Schedin and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Zhenzhen ZhangDivision of Oncological Sciences, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0002-9440-3892
Grace CurranKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Jackilen ShannonDivision of Oncological Sciences, Oregon Health & Science University, Portland, OR 97239, USA.ORCID 0000-0001-5377-9511
Ellen M VelieZilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI 53205, USA.ORCID 0000-0001-6865-9715
Veronica L IrvinCollege of Public Health and Human Sciences, Oregon State University, Corvallis, OR 97330, USA.ORCID 0000-0001-6337-9108
JoAnn E MansonDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Michael S SimonKarmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48202, USA.
Duygu Altinok DindarKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Chelsea PyleDepartment of Radiology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Pepper SchedinKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Fred K TabungDepartment of Internal Medicine, Division of Medical Oncology, College of Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0001-8193-7150
Oregon Health & Science University · USBrigham and Women's Hospital · USMedical College of Wisconsin · USOregon State University · USThe Ohio State University · USWayne State University · US

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Scholars in Women's Health Research Across the LifespanK12HD043488 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MYATT, LESLIE · 2002 to 2023
$10.4M
NCI NIH HHS P30 CA069533NICHD NIH HHS K12 HD043488NIH HHS K12HD043488
6 · The paper itself

Abstract

Interval breast cancer refers to cancer diagnosed after a negative screening mammogram and before the next scheduled screening mammogram. Interval breast cancer has worse prognosis than screening-detected cancer. Body mass index (BMI) influences the accuracy of mammography and overall postmenopausal breast cancer risk, yet how is obesity associated with postmenopausal interval breast cancer incidence is unclear. The current study included cancer-free postmenopausal women aged 50-79 years at enrollment in the Women's Health Initiative who were diagnosed with breast cancer during follow-up. Analyses include 324 interval breast cancer cases diagnosed within one year after the participant's last negative screening mammogram and 1969 screening-detected breast cancer patients. Obesity (BMI ≥ 30 kg/m

Indexed as

BMIbreast cancerinterval breast cancerobesityWHI

Identifiers

PMID35804998
PMCPMC9264843
OpenAlexW4283766256

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.